Angiotensin I converting enzyme inhibitors and angiotensin II receptor antagonists

  • Paul E. De Jong
Chapter

Summary

Soon after the introduction of ACEI much attention was given to their renal side effects. This initiated a lot of research, especially because hypertension frequently is present in patients with renal vascular and/or parenchymal disease and the use of ACEI therefore was prompted in such patient groups. In the early eighties nephrotic syndrome due to a membranous glomerulopathy was described in association with the use of captopril. Further detailed studies showed this side effect to be related to the very high doses that at that time were used in patients with renal disease. More common is the acute renal functional deterioration that may occur during ACEI in certain groups, such as in patients with renovascular hypertension, in patients with severe heart failure and in patients with severe renal failure, especially in case of volume depletion. However, this fall in filtration is reversible after withdrawal of the drug or after volume repletion. This finding of a renal hemodynamically mediated fall in intra-glomerular capillary pressure prompted studies that provided evidence of an antiproteinuric and renoprotective effect of this class of drugs. Close monitoring of side effects of drugs such as ACEI along with a basic understanding of the role of the renin angiotensin system in patients with renal diseases opens new perspectives for the treatment of such patients.

Keywords

Renal Artery Stenosis Renovascular Hypertension Acute Interstitial Nephritis Renal Perfusion Pressure Transplant Renal Artery Stenosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hoorntje SJ, Kallenberg CGM, Weening JJ, Donker AJM, The TH, Hoedemaeker PJ. Immune complex glomerulopathy in patients treated with captopril. Lancet 1980; 1: 1212–1214.PubMedGoogle Scholar
  2. 2.
    Prins EJL, Hoorntje SJ, Weening JJ, Donker AJM. Nephrotic syndrome in a patient on captopril. Lancet 1979; 2: 306.PubMedGoogle Scholar
  3. 33.
    Sturgill BC, Shearlock KT. Membranous glomerulopathy and nephrotic syndrome after captopril therapy. JAMA 1983; 250: 2343–2345.CrossRefPubMedGoogle Scholar
  4. 4.
    Kallenberg CGM, van der Laan S, de Zeeuw D. Captopril and the immune system. Lancet 1981; 2: 92.PubMedGoogle Scholar
  5. 5.
    Captopril: benefits and risks in severe hypertension. Editorial. Lancet 1980; 2: 129–130.Google Scholar
  6. 6.
    Lewis EJ and the Captopril Collaborative Study Group. Proteinuria and abnormalities of the renal glomerulus in patients with hypertension. Clin Exp Pharmacol Physiol 1982; 7: 105–115.Google Scholar
  7. 7.
    Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984; 144: 1947–1953.Google Scholar
  8. 8.
    Lewis EJ. Captopril and membranous glomerulopathy. JAMA 1984; 252; 7: 900.Google Scholar
  9. 9.
    Captopril Collaborative Study Group. Does Captopril cause renal damage in hypertensive patients? Report from the Captopril Collaborative Study Group. Lancet 1982; 1: 988–990.Google Scholar
  10. 10.
    Smit AJ, Hoorntje SJ, Weening JJ, Donker AM, Hoedemaeker PJ. Unilateral membranous glomerulopathy during captopril treatment. Neth J Med 1985; 28: 23–27.PubMedGoogle Scholar
  11. 11.
    Luderer JR, Schoolwerth AC, Sinicopre RA, Ballard JO, Lookingbill DP, Hayes AH. Acute renal failure, hemolytic anemia and skin rash associated with captopril therapy. Am J Med 1981; 71: 493–496.CrossRefPubMedGoogle Scholar
  12. 12.
    Cahan DH, Ucci AA. Acute renal failure, interstitial nephritis, and nephrotic syndrome associated with captopril. Kidney Int 1984; 25: 160.Google Scholar
  13. 13.
    Chauveau P, Rouveix B, Kleinknecht D. Insuffiscance rénale aiguè ďorigine immuno-allergique apres captopril. Néphrologie 1985; 6: 193–194.PubMedGoogle Scholar
  14. 14.
    Hooke D, Walker RG, Walter NMA, D’Apice AJF, Whitworth JA, Kincaid-Smith P. Repeated renal failure with use of captopril in a cystinotic renal allograft recipient. Brit Med J 1982; 285: 1538.Google Scholar
  15. 15.
    Islam S, Dubigeon MP, Guenel J. Néphropathie interstitielle granulomateuse aiguè et réversible apres traitement par le captopril. Rev Méd Interne (Paris) 1990; 11: 231.Google Scholar
  16. 16.
    Smith WR, Neill J, Cusham WC, Butkus DE. Captopril associated acute interstitial nephritis. Am J Nephrol 1989; 9: 230–235.PubMedGoogle Scholar
  17. 17.
    Steinman TI, Silva P. Acute renal failure, skin rash, and eosinophilia associated with captopril therapy. Am J Med 1983; 75: 154–151.CrossRefPubMedGoogle Scholar
  18. 18.
    Cressman MD, Vidt DG, Acker C. Renal glucosuria and azotaemia after enalapril maleate. Lancet 1982; 2: 440.PubMedGoogle Scholar
  19. 19.
    Jójárt GY, Sonkodi S. Does captopril induce glucosuria? Brit Med J 1984; 288: 368.Google Scholar
  20. 20.
    Hall JE, Guyton AC, Jackson TE, Coleman TG, Lohmeier TE, Trippodo NC. Control of glomerular filtration rate by reninangiotensin system. Am J Physiol 1977; 233: F366–F372.PubMedGoogle Scholar
  21. 21.
    Hall JE, Coleman TG, Guyton AC, Kastner PR, Granger JP. Control of glomerular filtration rate by circulating angiotensin II. Am J Physiol 1981; 241: R190–R197.PubMedGoogle Scholar
  22. 22.
    Woodhouse K, Farrow PR, Wilkinson R. Reversible renal failure during treatment with captopril. Brit Med J 1979; 2: 1146–1147.PubMedGoogle Scholar
  23. 23.
    Collste P, Haglund K, Lundgren G, Magnusson G, Östman J. Reversible renal failure during treatment with captopril. Brit Med J 1979; 2: 612–613.PubMedGoogle Scholar
  24. 24.
    Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenoses or renal artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373–376.PubMedGoogle Scholar
  25. 25.
    Textor SC, Tarazi FM, Novick AC, Bravo EL, Fouad FM. Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril. Am J Med 1984; 76 (suppl): 29–37.CrossRefPubMedGoogle Scholar
  26. 26.
    Mason JC, Hilton PJ. Reversible renal failure due to captopril in a patient with transplant artery stenosis: case report. Hypertension 1983; 5: 623–627.PubMedGoogle Scholar
  27. 27.
    van Son WJ, Donker AJM, Van der Woude FJ, Meijer S, Slooff MJH, Tegzess AM, Van der Slikke LB. Deterioration of renal function after converting enzyme inhibition in a patient with renal artery stenosis after transplantation. Neth J Med 1984; 27: 10–13.PubMedGoogle Scholar
  28. 28.
    Anderson WP, Korner PI, Johnston CI, Angus JA, Casley DJ. Intrarenal actions of angiotensin II in restoring renal artery pressure after acute renal artery stenosis. Clin Exp Pharmacol Physiol 1978; 5: 529–533.PubMedGoogle Scholar
  29. 29.
    Anderson WP, Denton KM, Woods RL, Alcorn D. Angiotensin II and the maintenance of GFR and renal blood flow during renal artery narrowing. Kidney Int 1990; 38 (suppl 30): 109–113.Google Scholar
  30. 30.
    Curtis JJ, Luke RG, Whelchel JD, Diethelm AG, Jones P, Dustan HP. Inhibition of angiotensin converting enzyme in renal transplant recipients with hypertension. N Engl J Med 1983; 308: 377–381.PubMedGoogle Scholar
  31. 31.
    Wenting GJ, Tan-Tjiong HL, Derckx FHM, de Bruyn JHB, Man in’ t Veld AJ, Schalekamp MADH. Split renal function after captopril in unilateral renal artery stenosis. Brit Med J 1984; 288: 886–890.Google Scholar
  32. 32.
    Hollenberg NK. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril. Am J Med 1984; 76 (suppl 5B): 22–28.PubMedGoogle Scholar
  33. 33.
    Watson ML, Bell GM, Muir AL, Buist TAS, Kellett RJ, Padfield PL. Captopril/diuretic combinations in severe renovascular disease: a cautionary note. Lancet 1983; 2: 404–405.PubMedGoogle Scholar
  34. 34.
    Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103: 222–223.PubMedGoogle Scholar
  35. 35.
    Andreucci VE, Conte G, Dal Canton A, Di Minno G, Usberti M. The causal role of salt depletion in acute renal failure due to captopril in hypertensive patients with a single functioning kidney and renal artery stenosis. Renal Failure 1987; 10: 9–20.PubMedGoogle Scholar
  36. 36.
    Jackson B, McGrath BP, Matthews PG, Wong C, Johnston CI. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 1986; 8: 650–654.PubMedGoogle Scholar
  37. 37.
    Reams GP, Bauer JH, Gaddy P. Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Hypertension 1986; 8: 290–297.PubMedGoogle Scholar
  38. 38.
    Franklin SS, Smith RD. A comparison of enalapril plus hydrochlorothiazide with standard triple therapy in renovascular hypertension. Nephron 1986; 44 (suppl 1): 73–82.PubMedGoogle Scholar
  39. 39.
    Jackson B, Franze L, Sumithran E, Johnston CI. Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 1990; 115: 21–27.PubMedGoogle Scholar
  40. 40.
    Hoefnagels WHL, Thien T. Renal artery occlusion in patients with renovascular hypertension treated with captopril. Brit Med J 1986; 292: 24–25.Google Scholar
  41. 41.
    Hodsman GP, Brown JJ, Cumming AMM, Davies DL, East BW, Lever AF, Morton JJ, Murray GD, Robertson JIS. Enalapril in treatment of hypertension with renal artery stenosis. Am J Med 1984; 77 (2A): 52–59.PubMedGoogle Scholar
  42. 42.
    Cleland JGF, Dargie HJ, Gillen G, Robertson I, East BW, Ball SG, Morton JJ, Robertson JIS. Captopril in heart failure: a double blind study of the effects on renal function. J Cardiovasc Pharmacol 1986; 8: 700–706.PubMedGoogle Scholar
  43. 43.
    Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106: 346–354.PubMedGoogle Scholar
  44. 44.
    Mujais SK, Fouad FM, Textor SC, Tarazi RC, Bravo EL, Hart N, Gifford RW. Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Brit Heart J 1984; 52: 63–71.PubMedGoogle Scholar
  45. 45.
    Verbeelen DL, de Boel S. Reversible acute on chronic renal failure during captopril treatment. Brit Med J 1984; 289: 20–21.Google Scholar
  46. 46.
    Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Brit Med J 1984; 288: 844–845.Google Scholar
  47. 47.
    Brivet F, Roulot D, Poitrine A, Dormont J. Reversible acute renal failure during enalapril treatment in patient with chronic glomerulonephritis without renal artery stenosis. Lancet 1985; 1: 1512.PubMedGoogle Scholar
  48. 48.
    Chapman AB, Gabow PA, Schrier RW. Reversible renal failure associated with angiotensin converting enzyme inhibitors in polycystic kidney disease. Ann Intern Med 1991; 115: 769–773.PubMedGoogle Scholar
  49. 49.
    Navis GJ, de Jong PE, de Zeeuw D. Volume homeostasis, angiotensin converting enzyme inhibition, and lithium therapy. Am J Med 1989; 86: 621.CrossRefPubMedGoogle Scholar
  50. 50.
    Speirs CJ, Dollery CT, Inman WHW, Rawson NSB, Wilton LV. Postmarketing surveillance of enalapril. II: Investigation of the potential role of enalapril in deaths with renal failure. Brit Med J 1988; 297: 830–832.PubMedGoogle Scholar
  51. 51.
    Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrotic view of converting enzyme inhibition. Am J Cardiol 1987; 60: 179–184.CrossRefPubMedGoogle Scholar
  52. 52.
    Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. Sth Med J 1990; 83: 1144–1148.Google Scholar
  53. 53.
    Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 1990; 10 suppl 1: 94–97.PubMedGoogle Scholar
  54. 54.
    Heeg JE, de Jong PE, de Zeeuw D. Additive antiproteinuric effect of angiotensin converting enzyme inhibition and nonsteroidal anti-inflammatory drug therapy: a clue to the mechanism of action. Clin Science 1991; 81: 367–372.Google Scholar
  55. 55.
    Rosa FW, Bosco LA, Fossum-Graham C, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin-converting enzyme inhibition. Obstet Gynecol 1989; 74: 371–374.PubMedGoogle Scholar
  56. 56.
    Brent RL, Beckman DA. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counsellors. Teratology 1991: 43: 543–546.CrossRefPubMedGoogle Scholar
  57. 57.
    Knott PD, Thorp SS, Lamont CAR. Congenital renal dysgenesis possibly due to captopril. Lancet 1989; 1: 451.PubMedGoogle Scholar
  58. 58.
    Cunnif C, Jones KL, Philipson K, Short S, Wujek J. Oligohydramnios and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 1990; 162: 187–189.Google Scholar
  59. 59.
    Pryde PG, Sedman AB, Nugent CE, Barr M. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 1993; 3: 1575–1582.PubMedGoogle Scholar
  60. 60.
    Barr M Jr. Teratogen Update: Angiotensine-Converting Enzyme Inhibitors. Teratology 1994; 50: 399–409.PubMedGoogle Scholar
  61. 61.
    Kreft-Jais C, Plouin C, Tchobroutsky C, Boutroy MJ. Angiotensin-converting enzyme inhibitors during pregnancy: A survey of 22 patients given captopril and nine give enalapril. Br J Obstet Gynaecol 1988; 95: 420–422.PubMedGoogle Scholar
  62. 62.
    Martin RA, Jones KL, Mendoza A, Barr M, Benirschke K. Effect of ACE inhibition on the fetal kidney: decreased renal blood flow. Teratology 1992; 46: 317–321.PubMedGoogle Scholar
  63. 63.
    Landing BH, Ang SM, Herta N, Larson EF, Turner M. Labeled lectin studies of renal tubular dysgenesis and renal tubular atrophy of postnatal renal ischemia and end-stage kidney disease. Pediatr Pathol 1994; 14: 87–99.PubMedGoogle Scholar
  64. 64.
    Simeoni U, Messer J, Weisburd P, Haddad J, Willard D. Neonatal renal dysfunction and intrauterine exposure to prostaglandin synthesis inhibitors. Eur J Pediatr 1989; 149: 371–373.Google Scholar
  65. 65.
    Restaino I, Kaplan BS, Kaplan P, Rosenberg HK, Witzleben C, Roberts N. Renal dysgenesis in a monozygotic twin: Association with in utero exposure to indomethacin. Am J Med Genet 1991; 39: 252–257.CrossRefPubMedGoogle Scholar
  66. 66.
    Bavoux F. Toxicite foetal des anti-inflammatoires non steroidiens. Presse Med 1992; 21: 1909–1912.PubMedGoogle Scholar
  67. 67.
    Buderes S, Thomas B, Fahnenstich H, Kowalewski S. Renal failure in two preterm infants: toxic effect of prenatal maternal indomethacin treatment. Br J Obstet Gynaecol 1993; 100: 97–98.Google Scholar
  68. 68.
    Voyer LE, Drut R, Mendez JH. Fetal renal maldevelopment with oligohydramnios following maternal use of piroxicam. Pediatr Nephrol 1994; 8: 592–594.CrossRefPubMedGoogle Scholar
  69. 69.
    Nally JV Jr, Clarke HS Jr, Grews GP, Saunders M, Gross ML, Potvin WJ, Windham JP. Effect of captopril on 99mTc-diethylenetriaminepentaacetic acid renograms in two-kidney, one clip hypertension. Hypertension 1986; 8: 685–693.PubMedGoogle Scholar
  70. 70.
    Jonker GJ, de Zeeuw D, Huisman RM, Piers DA, Beekhuis H, van der Hem GK. Angiotensin converting enzyme inhibition improves diagnostic procedures for renovascular hypertension in dogs. Hypertension 1988; 12: 411–419.PubMedGoogle Scholar
  71. 71.
    Geyskes GG, Oei HY, Puylaert CBAJ, Dorhout Mees EJ. Renovascular hypertension identified by captopril-induced changes in the renogram. Hypertension 1987; 9: 451–458.PubMedGoogle Scholar
  72. 72.
    Kremer Hovinga TK, de Jong PE, Piers DA, Beekhuis H, van der Hem GK, de Zeeuw D. Diagnostic use of ACE inhibitors in radioisotope evaluation of unilateral renal artery stenosis. J Nucl Med 1989; 30: 605–614.PubMedGoogle Scholar
  73. 73.
    Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986; 146: 2145–2148.CrossRefPubMedGoogle Scholar
  74. 74.
    Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78–83.PubMedGoogle Scholar
  75. 75.
    Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–279.PubMedGoogle Scholar
  76. 76.
    Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202–206.PubMedGoogle Scholar
  77. 77.
    Pelayo JC, Quan AH, Shanley PF. Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiol 1990; 258: F414–F422.PubMedGoogle Scholar
  78. 78.
    Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. Clin Invest 1985; 76: 612–619.Google Scholar
  79. 79.
    Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishazaki M, Takahashi H, Sekino H, Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetes. N Engl J Med 1985; 313: 1617–1620.PubMedGoogle Scholar
  80. 80.
    Bjorck S, Mulec H, Johnsen SA, Nyberg G, Aurell M. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Brit Med J 1990; 300: 904–907.PubMedGoogle Scholar
  81. 81.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.PubMedGoogle Scholar
  82. 82.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.CrossRefPubMedGoogle Scholar
  83. 83.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–859.PubMedGoogle Scholar
  84. 84.
    Parving HH, Lehnert H, Bröchner-Mortensen, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med 2001; 345: 870–878.Google Scholar
  85. 85.
    Brenner BM, Cooper MA, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn S, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.CrossRefPubMedGoogle Scholar
  86. 86.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.CrossRefPubMedGoogle Scholar
  87. 87.
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857–1863.Google Scholar
  88. 88.
    Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–364.PubMedGoogle Scholar
  89. 89.
    Jafar T, Schmid C, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey A, for the ACE-inhibition in progressive renal disease Study Group. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73–87.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Paul E. De Jong
    • 1
  1. 1.University of GroningenThe Netherlands

Personalised recommendations